Your browser doesn't support javascript.
loading
Use of Measles and Rubella Rapid Diagnostic Tests to Improve Case Detection and Targeting of Vaccinations.
Rachlin, Audrey; Hampton, Lee M; Rota, Paul A; Mulders, Mick N; Papania, Mark; Goodson, James L; Krause, L Kendall; Hanson, Matt; Osborn, Jennifer; Kelly-Cirino, Cassandra; Evans, Beth; Sinha, Antara; Warrener, Lenesha; Featherstone, David; Brown, David.
Afiliación
  • Rachlin A; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
  • Hampton LM; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
  • Rota PA; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
  • Mulders MN; Department of Immunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland.
  • Papania M; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
  • Goodson JL; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
  • Krause LK; Bill & Melinda Gates Foundation, Seattle, WA 98109, USA.
  • Hanson M; Sound Global Health Consulting, LLC, Seattle, WA 98199, USA.
  • Osborn J; Foundation for Innovative New Diagnostics (FIND), 1218 Geneva, Switzerland.
  • Kelly-Cirino C; Foundation for Innovative New Diagnostics (FIND), 1218 Geneva, Switzerland.
  • Evans B; Gavi, the Vaccine Alliance, Global Health Campus, 1218 Geneva, Switzerland.
  • Sinha A; Institute of Global Health, Faculty of Medicine, University of Geneva, 1202 Geneva, Switzerland.
  • Warrener L; Gavi, the Vaccine Alliance, Global Health Campus, 1218 Geneva, Switzerland.
  • Featherstone D; Public Health Microbiology Division, UK Health Security Agency (UKHSA), London NW9 5EQ, UK.
  • Brown D; Consultant Scientists Ltd., Hastings 4122, New Zealand.
Vaccines (Basel) ; 12(8)2024 Jul 23.
Article en En | MEDLINE | ID: mdl-39203949
ABSTRACT
Efforts to control and eliminate measles and rubella are aided by high-quality surveillance data-supported by laboratory confirmation-to guide decision-making on routine immunization strategies and locations for conducting preventive supplementary immunization activities (SIAs) and outbreak response. Important developments in rapid diagnostic tests (RDTs) for measles and rubella present new opportunities for the global measles and rubella surveillance program to greatly improve the ability to rapidly detect and respond to outbreaks. Here, we review the status of RDTs for measles and rubella Immunoglobulin M (IgM) testing, as well as ongoing questions and challenges regarding the operational use and deployment of RDTs as part of global measles and rubella surveillance. Efforts to develop IgM RDTs that can be produced at scale are underway. Once validated RDTs are available, clear information on the benefits, challenges, and costs of their implementation will be critical for shaping deployment guidance and informing country plans for sustainably deploying such tests. The wide availability of RDTs could provide new programmatic options for measles and rubella elimination efforts, potentially enabling improvements and flexibility for testing, surveillance, and vaccination.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos